How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,013 results for

Glucose Tolerance Test 3 hour

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Postprandial Blood Glucose and Insulin Levels Following Consumption of Lentil-containing Food Products

of muffins, soup and chilli, with and without lentils. Participants will then have their blood sampled for the following 2 hours by finger prick. Participants will remain seated during the test period. All study visits will occur at the Human Nutraceutical Research Unit and be separated by a washout period of 3-7 days. Throughout the study, it will be asked that participants' lifestyle and physical activity remain unchanged. Participants will be instructed to not start any new dietary approaches (...) blood glucose >11.1 mmol/L post-75g OGTT) 1 Impaired Glucose Tolerance (IGT) (Fasting blood glucose 6.1-6.9 mmol/L and/or 2hr blood glucose 7.8-11.0 mmol/L post-75g OGTT) 1 Blood pressure >140/90 mm Hg Any major medical condition including a history of AIDS or hepatitis Medical or surgical event requiring hospitalization within 3 months of randomization Any medications except a stable dose (3 months) of oral contraceptives, blood pressure or statin medications Natural health products (NHPs) used

2016 Clinical Trials

102. Effect of Fasting Therapy on Blood Glucose Control and Islet Function in Newly Diagnosed Type 2 Diabetic Patients

/treatment Experimental: Fasting therapy Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs. Other: Fasting therapy The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l (...) participant will be monitored to assess the long-term remission rate of diabetes. Patients are invited to review their glucose and lipid metabolic indices at 3 months, 6 months and 12 months of follow-up. Lifestyle guidance will be offered by specialist physicians throughout the follow-up period. Secondly, all the patients are required to take the insulin and C-peptide releasing tests before and after fasting as well as in the follow-up to investigate the short-term and long-term treatment effect of islet

2016 Clinical Trials

103. Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers

in the trial unit for approx. 4 hours/ week for 4 times in a row with approx. 1 week of washout in between Signed informed consent form Exclusion Criteria: Known (family) history of diabetes mellitus or use of anti-hyperglycaemic drugs or Insulin Clinically relevant renal or hepatic disease, liver enzymes > 10% above reference range Fasting blood glucose > 100 mg/dL or HbA1c outside of reference range Total cholesterol > 250 mg/dL or triglycerides > 150 mg/dL Haemoglobin < 11 g/dL (women); < 12.5 g/dL (men (...) ) BMI < 19 kg/m² and ≥ 30 kg/m² Intentional and unintentional weight loss > 5% in the previous 6 months Smoker Major medical or surgical event requiring hospitalization within the previous 3 months Presence of disease or drug(s) influencing digestion and absorption of nutrients or bowel habits Intake of medications known to affect glucose tolerance, e.g., steroids, protease inhibitors or antipsychotics (stable doses of e.g., oral contraceptives, thyroxin, vitamins and mineral supplements or drugs

2016 Clinical Trials

104. Various Serving Sizes of Lentils on Blood Glucose and Insulin

Ages Eligible for Study: 18 Years to 40 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria Healthy men and women Age 18-40 years Body mass index (BMI) 20-30 kg/m2 Exclusion Criteria: Tobacco use Pregnant or breastfeeding Fasting blood glucose ≥ 7.0 mmol/L Two hour blood glucose ≥ 11.1 mmol/L after consuming 75g glucose drink (Oral Glucose Tolerance Test beverage) Any major medical condition including a history of AIDS or hepatitis Medical (...) Various Serving Sizes of Lentils on Blood Glucose and Insulin Various Serving Sizes of Lentils on Blood Glucose and Insulin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Various Serving Sizes of Lentils

2016 Clinical Trials

105. A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM

(Humalog®) individualised single subcutaneous injection followed by test meal intake Active Comparator: Huminsulin® Normal Drug: Regular human insulin (Huminsulin® Normal) Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake Outcome Measures Go to Primary Outcome Measures : BG1h [ Time Frame: 1 hour ] Blood glucose (BG) concentration 1 hour after start of intake of a standardised meal Secondary Outcome Measures : ΔBG1h [ Time Frame: 1 hour (...) ] Mean change from baseline of blood glucose concentration 1 hour after start of intake of a standardised meal AUCBG,0-1h [ Time Frame: 1 hour ] Area under the blood glucose concentration-time curve from 0-1 hour after a standardised meal ΔAUCBG,0-1h [ Time Frame: 1 hour ] Incremental area under the blood glucose concentration-time curve from 0-1 hour after a standardised meal AUCIns,0-1h [ Time Frame: 1 hour ] Area under the serum insulin concentration-time curve from 0-1 hour Adverse Events [ Time

2016 Clinical Trials

106. A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

subcutaneous injections Drug: Humalog® Injection of Humalog® Drug: Lantus® Injection of Lantus® Outcome Measures Go to Primary Outcome Measures : Delta AUC BG 0-2h (area under the blood glucose concentration-time curve) [ Time Frame: From 0 to 2 hours ] Mean of incremental areas under the blood glucose concentration-time curve from 0-2 hours after a standardised meal on Day 2 and Day 3 Secondary Outcome Measures : Partial delta AUCs BG and total AUCs BG [ Time Frame: From 0 to 6 hours ] Partial incremental (...) , 3-treatment, 3-period cross-over study using a standardised solid meal test in subjects with type 2 diabetes to investigate postprandial glucose control of BioChaperone® Combo compared with Humalog® Mix25 and with simultaneous subcutaneous injections of Humalog® and Lantus® during three separate dosing visits. Furthermore, this study aims to compare the pharmacokinetic (PK) profiles of the three different study treatments. During each dosing visit, subjects will be given 3 doses of IMP on three

2016 Clinical Trials

107. Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

meal tolerance test [ Time Frame: After 13 days of AMG 151 or placebo treatment ] 4-hour concentration time profile of glucose after the mixed meal tolerance test [ Time Frame: After 13 days of AMG 151 or placebo treatment ] Safety end points will include the incidence of treatment emergent adverse events. [ Time Frame: Up to 2 Months ] Serum AMG 151 concentration [ Time Frame: Up to 2 Months ] Safety end points will include laboratory safety tests. [ Time Frame: Up to 2 Months. ] Safety end points (...) Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2012 Clinical Trials

108. Is an Oral Glucose Tolerance Test Still Valid for Diagnosing Diabetes Mellitus? Full Text available with Trip Pro

Is an Oral Glucose Tolerance Test Still Valid for Diagnosing Diabetes Mellitus? We evaluated the diagnostic rate of diabetes using fasting plasma glucose (FPG), 2-hour plasma glucose (2h PG) after 75 g oral glucose tolerance test (OGTT), and glycosylated hemoglobin (HbA1c) levels, and we elucidated the pathophysiologic characteristics and risk factors that give rise to diabetes in patients with prediabetes.The data of 236 patients who had the OGTT at Konkuk University Hospital were analyzed (...) . Fasting, 30, and 120 minutes blood glucose levels and insulin levels were measured. The diagnostic rate of diabetes was assessed using FPG, 2h PG, and HbA1c levels. The clinical data and insulin resistance and secretion evaluations were compared using indexes according to the fasting glucose level.Among 236 subjects, 97 (41.1%) were diabetics and 102 (43.2%) were prediabetics. The rate of diabetes diagnosis by one of the individual criteria was 56.7%, 53.6%, and 84.5% for FPG, HbA1c, and 2h PG

2015 Diabetes & metabolism journal

109. Is There a Threshold Oral Glucose Tolerance Test Value for Predicting Adverse Pregnancy Outcome? Full Text available with Trip Pro

Is There a Threshold Oral Glucose Tolerance Test Value for Predicting Adverse Pregnancy Outcome? This study aims to determine whether there is a threshold 3-hour oral glucose tolerance test (OGTT) value associated with accelerated risk of adverse pregnancy outcomes.In a secondary analysis of a cohort of women with untreated mild gestational glucose intolerance, we used generalized additive models with smoothing splines to explore nonlinear associations between each of the 3-hour OGTT values (...) (fasting, 1-hour, 2-hour, and 3-hour) and adverse pregnancy outcomes, including the study's composite outcome (perinatal mortality, hypoglycemia, hyperbilirubinemia, neonatal hyperinsulinemia, and/or birth trauma), large for gestational age birth weight, small for gestational age birth weight, shoulder dystocia, neonatal hypoglycemia, gestational hypertension (gHTN), and preeclampsia.Among the 1,360 eligible women, each timed OGTT value was linearly associated with increased odds of composite adverse

2015 American journal of perinatology Controlled trial quality: uncertain

110. Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients

at maximal cardiopulmonary exercise test [CPX]) will be assigned to a single-arm open-label dietary intervention in which subjects are encouraged and financially supported to increase daily UFA consumption. The investigators will measure dietary compliance with a validated 24-hour dietary recall and with objective operator-independent biomarkers of UFA consumption. The investigators will also measure the effects of UFA supplementation on: metabolic flexibility, glucose tolerance and body composition (...) Outcome Measures : Change in metabolic flexibility [ Time Frame: At baseline and 12 weeks ] Area under the curve change of respiratory quotient measured during overnight stay for 14 hours in the WIC Change in body composition [ Time Frame: At baseline and at 12 weeks ] Assessed by dual energy X-ray absorptiometry (DXA) Change in glucose tolerance [ Time Frame: At baseline and at 12 weeks ] Oral glucose tolerance test (OGTT) measures plasma glucose and insulin Eligibility Criteria Go to Information

2017 Clinical Trials

111. Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture

] The fasting plasma glucose (FPG) is used to diagnose diabetes. IGT can be diagnosed base on FPG less than 7.0 mmol/L. OGGT [ Time Frame: Baseline and 6 week, 12 weeks ] The 2-hour plasma glucose after a 75-g oral glucose tolerance test (OGTT) is used to diagnose diabetes. IGT can be diagnosed base on 2-hour plasma Glucose between 7.8 and 11.1 mmol/L. Secondary Outcome Measures : BMI [ Time Frame: Baseline and 12 weeks ] The body mass index are used to diagnose Obesity. Weight and height will be combined (...) Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2017 Clinical Trials

112. Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.

Model: Crossover Assignment Intervention Model Description: Subjects complete three oral glucose tolerance tests (OGTT) on different days, with a minimum of one week in between. First visit is a combined screening and baseline OGTT, with no supplementation. At the second and third visit subjects are randomly assigned to either 3 g of hydrolyzed pine nut oil or 6 g of hydrolyzed pine nut oil. Masking: None (Open Label) Primary Purpose: Basic Science Official Title: Dose-response Effect of Pine Nut (...) glucose [ Time Frame: 4 hours OGTT ] Area under the curve of blood glucose Insulin and C-peptide [ Time Frame: 4 hours OGTT ] Area under the curve of Insulin and C-peptide Incretins [ Time Frame: 4 hours OGTT ] Area under the curve of incretins ghrelin [ Time Frame: 4 hours OGTT ] Area under the curve of ghrelin appetite [ Time Frame: 4 hours OGTT ] Visual analog scale - area under the curve Gastrointestinal tolerability [ Time Frame: 4 hours OGTT ] Visual analog scale -mm Eligibility Criteria Go

2017 Clinical Trials

113. Effect of Preconception Impaired Glucose Tolerance on Pregnancy Outcomes in Women with Polycystic Ovary Syndrome. Full Text available with Trip Pro

Effect of Preconception Impaired Glucose Tolerance on Pregnancy Outcomes in Women with Polycystic Ovary Syndrome. Women with polycystic ovary syndrome (PCOS) commonly have intrinsic insulin resistance and are recommended to undergo an oral glucose tolerance test (OGTT) for diabetes screening. However, the effect of preconception impaired glucose tolerance (IGT) on pregnancy is still unclear.To prospectively assess the effect of preconception IGT on pregnancy outcomes.This was a secondary (...) analysis of a multicenter randomized trial in 1508 women with PCOS comparing live birth and obstetric complications between fresh and frozen embryo transfer. At baseline, fasting and 2-hour glucose and insulin levels after 75-g OGTT were measured.Women with preconception IGT had higher risks of gestational diabetes in both singleton pregnancy [9.5% vs 3.2%; odds ratio (OR) 3.13; 95% confidence interval (CI) 1.23to 7.69] and twin pregnancy (20.0% vs 3.2%; OR 7.69; 95% CI 2.78 to 20.00) than women

2017 Journal of Clinical Endocrinology and Metabolism

114. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. (Abstract)

%). Pharmacodynamic variables were well correlated to RG7697 average plasma concentration during MTT, with IC50 (average concentration required for 50% reduction) values of 49 and 24.5 ng/mL for glucose and insulin, respectively.Single s.c. injections of RG7697 up to 3.6 mg were generally well tolerated. Evidence of glycaemic effect and pharmacokinetic profiles consistent with once-daily dosing render this drug candidate suitable to be further tested in multiple-dose clinical trials in patients with type 2 (...) Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. To evaluate the pharmacodynamics, pharmacokinetics and safety of single subcutaneous (s.c.) injection of ascending doses of RG7697, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist, in healthy subjects.A total of 51 healthy volunteers were

2017 obesity & metabolism Controlled trial quality: uncertain

115. HCV eradication by DAA improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1. (Abstract)

tolerance.To this aim, we performed a prospective study assessing the effects of direct antiviral agents treatment in nondiabetic cirrhotic patients with genotypes 1a/1b and impaired glucose tolerance based on a 75-g oral glucose tolerance test. Impaired glucose tolerance was diagnosed by a 2-hour plasma glucose between 140 and 199 mg/dL. Insulin resistance was estimated by the oral glucose insulin sensitivity index, an oral glucose tolerance test-derived measure.After meeting the inclusion criteria (...) HCV eradication by DAA improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1. Genotype 1 chronic hepatitis C is associated with an impairment of glucose homoeostasis, especially in the advanced stages of the disease. Glucose tolerance is an independent predictor of liver-related mortality in patients with cirrhosis because of chronic hepatitis C. However, no study has demonstrated so far weather hepatitis C virus clearance affects glucose

2017 Liver International

116. Glucose tolerance and insulin responsiveness in Gitelman syndrome patients Full Text available with Trip Pro

Glucose tolerance and insulin responsiveness in Gitelman syndrome patients Impaired glucose metabolism and insulin sensitivity have been reported in patients with Gitelman syndrome (GS), but insulin secretion and the related mechanisms are not well understood.The serum glucose levels, insulin secretion and insulin sensitivity were evaluated in patients with GS (n = 28), patients with type 2 diabetes mellitus (DM) and healthy individuals (n = 20 in both groups) using an oral glucose tolerance (...) test. Serum and urine sodium, potassium and creatinine levels were measured at 0, 30, 60, 120 and 180 min after an oral glucose load was administered.The areas under the serum glucose curves were higher in the GS patients than those in the healthy controls (17.4 ± 5.1 mmol·h/L vs 14.5 ± 2.8 mmol·h/L, P = 0.02) but lower than those in the DM patients (24.8 ± 5.3 mmol·h/L, P < 0.001). The areas under the serum insulin curves and the insulin secretion indexes in GS patients were higher than those

2017 Endocrine connections

117. C-Reactive Protein Concentrations and Level of Physical Activity in Men and Women With Normal and Impaired Glucose Tolerance. A Cross-Sectional Population-Based Study in Sweden. (Abstract)

C-Reactive Protein Concentrations and Level of Physical Activity in Men and Women With Normal and Impaired Glucose Tolerance. A Cross-Sectional Population-Based Study in Sweden. We aimed to explore the association between self-reported leisure time physical activity (LTPA) and C-reactive protein (CRP) concentrations in men and women with and without impaired glucose tolerance (IGT).In a cross-sectional study, a random sample (n = 2,816) was examined with an oral glucose tolerance test, CRP (...) and information about LTPA. Those with IGT or normal glucose tolerance (NGT) and CRP value ≤10 mg/L were selected (n = 2,367) for the study.An inverse association between LTPA and CRP concentrations was observed in the population (P < .001), though, only in men with IGT (P = .023) and in women with NGT. Men with IGT, reporting slight physical activity up to 4 hours a week presented significantly higher CRP concentrations than normoglycemic men (Δ0.6 mg/L, P = .004). However, this difference could not be found

2017 Journal of physical activity & health Controlled trial quality: uncertain

118. Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus

: Biochaperone® Combo Subcutaneous injection of an individualized dose Active Comparator: Humalog® Mix25 1 single dose 100 U/mL Drug: Humalog® Mix25 Subcutaneous injection of an individualized dose Outcome Measures Go to Primary Outcome Measures : Delta AUCBG,0-2h [ Time Frame: 2 hours ] Incremental area under the blood glucose concentration-time curve from 0-2 hours after a standardised meal Secondary Outcome Measures : Delta AUCBG,0-6h [ Time Frame: 6 hours ] Incremental area under the blood glucose (...) concentration-time curve from 0-6 hours after a standardised meal BGmax [ Time Frame: 6 hours ] Maximum blood glucose concentration after a standardised meal (0-6 hours) tBGmax [ Time Frame: 6 hours ] Time to maximum blood glucose concentration after a standardised meal (0-6 hours) AUCLisp,0-6h, [ Time Frame: 6 hours ] Area under the plasma insulin lispro concentration-time curve from 0-6 hours AUCGlarg,0-6h [ Time Frame: 6 hours ] Area under the plasma insulin glargine concentration-time curve from 0-6

2015 Clinical Trials

119. Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans

-prescription medications at the time of the study Having donated blood three months prior to and three months post study procedures A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded. Known allergy, hypersensitivity or contraindication to receiving study medications. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact (...) Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2015 Clinical Trials

120. Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog&#174;) After Ingestion of a Standardized Meal

injected subcutaneously Outcome Measures Go to Primary Outcome Measures : Area under the blood glucose time curve: AUCbg(0-2h) [ Time Frame: 2 hours ] Area under the blood glucose concentration time curve from 0-2 hours after a standardised meal Secondary Outcome Measures : Pharmacodynamic: Area under the blood glucose concentration time curve from 0-8 hours after a standardized meal: AUCbg(0-8h) [ Time Frame: 8 hours ] Pharmacodynamic: maximum blood glucose concentration after a standardized meal (...) Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>